ArcDia
Provides the most complete solutions for acute infection diagnosis with mariPOC rapid antigen tests.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
N/A | Series A | ||
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 7 % | 22 % | 66 % | 38 % | 26 % | (56 %) | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (114 %) | (59 %) | (12 %) | (15 %) | 9 % | (36 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (181 %) | (97 %) | (38 %) | (33 %) | (4 %) | (67 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 108 % | 176 % | 106 % | 116 % | - | - | - |
Source: Company filings or news article, Dealroom estimates
Related Content
ArcDia International Ltd. specializes in developing and distributing rapid diagnostic solutions for respiratory and gastrointestinal infections. The company operates primarily in the healthcare sector, serving clinical laboratories, hospitals, and research institutions. ArcDia's core product is based on its proprietary TPX detection technology, which allows for multianalyte rapid testing with a fully automated and random access test system. This technology is designed to be user-friendly, cost-efficient, and highly accurate, making it suitable for near-patient testing environments.
ArcDia's business model revolves around the sale and distribution of its diagnostic platforms and test kits. The company generates revenue through direct sales, licensing agreements, and partnerships with distributors. Since its inception, ArcDia has expanded its market presence to numerous countries and continues to seek new partners for further distribution.
The company has received several accolades, including the Frost & Sullivan Award for Point of Care Product Leadership in 2014. ArcDia's products are IVD CE marked, ensuring compliance with European standards for in vitro diagnostic devices. The company is a market leader in Finland for respiratory infection testing and aims to maintain its competitive edge through continuous innovation and product development.
Keywords: rapid diagnostics, TPX technology, respiratory infections, gastrointestinal infections, clinical laboratories, hospitals, near-patient testing, cost-efficient, IVD CE marked, market leader.